An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms FLUTEEN
- Sponsors Ellodi Pharmaceuticals
- 08 Nov 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2022 Planned End Date changed from 5 Aug 2022 to 26 Oct 2022.
- 06 Oct 2022 Planned primary completion date changed from 5 Aug 2022 to 26 Oct 2022.